hOX40/hOX40L(2)

Fig1. OX40 expression on CD4+ T cells in spleen in hOX40 KI mice.

Fig2. OX40 expression on Treg cells in spleen in hOX40 KI mice. 

Fig3. Detection of hOX40L expression on stimulated APCs in hOX40/hOX40L dKI mice.

Fig4. OX40 antibody showed dose-dependent anti-tumor activity in human OX40 knock-in mice bearing MC38 tumors.(The OX40 antibody was obtained from Innoventbio)

In vivo efficacy study of amlitelimab on OXA-induced AD model in hOX40/hOX40L mice

Fig.1 Cell number of CD45+ and eosinophils in BALF of HO OX40/OX40L humanized OVA-Induced asthma model 

Abbr. HO, homozygous; WT, wild type.

Fig 2. Effects of Amlitelimab on body weight and ear thickness in oxazolone (OXA)-induced atopic dermatitis. (A)Time course of body weight; (B) Time course of ear thickness.  

Fig 3. Alleviation of oxazolone (OXA)-induced atopic dermatitis clinical symptoms by Amlitelimab. (A)Cumulative clinical skin scores; (B) Time course of Erythema scores; (C) Time course of Skin thickness scores; (D) Time course of Scabby scores.

Fig 4. Representative photographs of H&E-stained skin sections.  (A) Representative H&E-stained sections of ear tissue. (B) Semi-quantitative pathology scores for ear sections.

Fig 5. Representative photographs of H&E-stained ear sections. The model group demonstrated angiogenesis and inflammatory cell infiltration in the dermis.

Fig 6. Serum IgE levels  in oxazolone (OXA)-induced atopic dermatitis.(A)Serum IgE levels measured at the endpoint.